Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:

Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
Global and Regional Antibody Drug Conjugate Market Insight
Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
Insight On Antibody Drug Conjugates In Clinical Trials: > 550 Drugs
Insight On Commercially Approved Antibody Drug Conjugates: > 15 Drugs
Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication and Phase
Global Cancer Antibody Drug Conjugate Market Trends by Indication

The realm of cancer treatment is experiencing a surge of innovation that may greatly change how we currently diagnose as well as treat cancer. Clinical researchers and pharmaceutical companies continue to seek innovative solutions that offer enhanced efficacy and reduced side effects. Among the ongoing significant advancements, antibody drug conjugates (ADCs) have emerged as a groundbreaker in cancer therapeutics. This rapidly expanding market is transforming the treatment landscape, offering a new therapeutic option for patients globally.

Antibody drug conjugates harness the synergistic potential of monoclonal antibodies and potent cytotoxic drugs, delivering a strong strike against cancer cells. By exploiting the specificity of monoclonal antibodies, antibody drug conjugates can selectively bind to cancer antigens, increasing drug delivery directly to tumor sites. This targeted approach enables higher drug concentrations at the desired location while minimizing harm to healthy, normal tissues.

The antibody drug conjugate market is experiencing remarkable growth, driven by several key factors including the increasing cancer incidence rates, rowing demand for effective and personalized treatment options and advancements in antibody engineering and drug delivery technologies are propelling the market forward. Moreover, regulatory approvals have opened the way for the commercial success of antibody drug conjugates which has further encouraged investments in the field.

For instance, Adcetris and Kadcyla have been in the market for a long time and their commercial sales hold a significant share of the current antibody drug conjugate market. The growth of these antibody drug conjugates represents the significant need for this therapeutic modality. Enhertu, another antibody drug conjugate which is relatively new to the market compared to Kadcyla and Adcetris, has shown immense success commercially. With its recent approval for breast cancer indication, the sales for Enhertu have escalated rapidly.

Antibody drug conjugates have welcomed a new age of targeted cancer therapy and this novel class of cancer treatment can be evaluated to have an exponential increase in terms of both commercial success as well as expansion of the global portfolio. However, the development of antibody drug conjugates has been associated with significant challenges with difficulties in manufacturing, bioconjugation and their overall development. Nevertheless, collaboration between pharmaceutical companies and academic institutions has been an important factor that has helped in overcoming these limitations, resulting in such success of antibody drug conjugates.

For instance, Lantern Pharma collaborating with Germany’s Bielefeld University will leverage its proprietary Artificial Intelligence platform RADR for the rapid development of novel cryptophycin antibody drug conjugates, representing an exciting new class of strong and highly directed drug candidates. It is expected that outcomes from this collaborative arrangement will pave the way for next generation antibody drug conjugated designed using AI with high efficacy, swift development with sibilant cost reduction.

The future of antibody drug conjugates is expected to be closely tangled with technological innovations. Novel conjugation strategies such as site specific conjugation are also being explored to enhance stability of antibody drug conjugates, resulting in improved therapeutic outcomes. Additionally, advancements in bioconjugation techniques, payload release mechanism and drug delivery systems offer opportunities to optimize the pharmacokinetics and bio distribution of antibody drug conjugates potentially increasing their effectiveness.

Antibody drug conjugates have targeted a new level of efficacy, surpassing the capabilities of traditional monoclonal antibodies and opening opportunities for market expansion. While monoclonal antibodies are highly specific in their binding to cancer cell antigens, their therapeutic impact often relies on the activation of immune responses or blocking signaling pathways. In contrast, antibody drug conjugates offer a multifaceted approach by directly delivering a potent cytotoxic payload to cancer cells, exerting a direct cell killing effect.

Overall, the antibody drug conjugates market represents a groundbreaking approach to cancer treatment. As market continues to expand, patients and healthcare professionals are witnessing significant advancements. With ongoing research, technological innovations and strategic collaborations, the future of antibody drug conjugates is set to transform the global cancer therapy market. Our report provides a comprehensive analysis about the currently approved antibody drug conjugates in terms of their patent, price, dosage as well as their sales and treatment cost. Furthermore, the report also provides information about the regional impact of approved antibody drug conjugates while also providing information about the possible future opportunities in the global antibody drug conjugates market.

Introduction to Antibody Drug Conjugates

1.1 Overview

1.2 Historical Development of ADCs

1.3 Evolution of Antibody Drug Conjugates

Need of Antibody Drug Conjugates

Global Antibody Drug Conjugate Market Insight

3.1 Current Market Scenario (2019 -2023)

3.2 Future Market Opportunity Assessment 2029

Antibody Drug Conjugate Market Regional Analysis

4.1 US

4.2 China

4.3 South Korea

4.4 India

4.5 Australia

4.6 Europe

4.7 Canada

4.8 Japan

4.9 Taiwan

Global Cancer Antibody Drug Conjugate Market Trends by Indication

5.1 Breast Cancer

5.2 Lung Cancer

5.3 Lymphoma

5.4 Leukemia

5.5 Cervical Cancer

5.6 Urothelial Cancer

5.7 Gastric Cancer

5.8 Other Cancers

Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight 2023

6.1 Mylotarg

6.2 Adcetris

6.3 Kadcyla

6.4 Besponsa

6.5 Lumoxiti

6.6 Polivy

6.7 Padcev

6.8 Enhertu

6.9 Trodelvy

6.10 Blenrep

6.11 Zynlonta

6.12 Tivdak

6.13 Elahere

6.14 Aidixi

6.15 Ujvira

6.16 Akalux

Approved Antibody Drug Conjugate Sales Insights (Global and Regional, Yearly and Quaterly, 2019 -2023)

7.1 Adcetris

7.2 Padcev

7.3 Tivdak

7.4 Polivy

7.5 Kadcyla

7.6 Besponsa

7.7 Enhertu

7.8 Trodelvy

7.9 Zynlonta

7.10 Elahere

7.11 Blenrep

Global Antibody Drug Conjugates Clinical Trials Insight 2023

8.1 By Phase

8.2 By Indication

8.3 By Company

8.4 By Patient Segment

8.5 By Country

Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication and Phase

9.1 Research

9.2 Preclinical

9.3 Phase-I

9.4 Phase-I/II

9.5 Phase-II

9.6 Phase-II/III

9.7 Phase-III

9.8 Preregistration

Marketed Cancer Antibody Drug Conjugates Clinical Insight

Global Cancer an Antibody Drug Conjugates Market Dynamics

11.1 Favorable Parameters

11.2 Challenges for Antibody Drug conjugates Market

Competitive Landscape

12.1 AbbVie

12.2 ADC Therapeutics

12.3 AstraZeneca

12.4 Bayer

12.5 BiOneCure Therapeutics

12.6 Biosion

12.7 Bio-Thera Solutions

12.8 Boehringer Ingelheim

12.9 Daiichi Sankyo Company

12.10 Duality Biologics

12.11 Exelixis

12.12 Genmab

12.13 Hangzhou DAC Biotech

12.14 Heidelberg Pharma AG

12.15 Iksuda Therapeutics

12.16 ImmunoGen

12.17 LaNova Medicines Limited

12.18 LegoChem Biosciences

12.19 Lepu Biopharma

12.20 Mersana Therapeutics

12.21 Molecular Templates

12.22 Multitude Therapeutics

12.23 NanoValent Pharmaceuticals

12.24 NewBio Therapeutics

12.25 Orum Therapeutics

12.26 ProfoundBio

12.27 Radiopharm Theranostics

12.28 Seagen

12.29 Sorrento Therapeutics

12.30 Sutro Biopharma

Figure 1-1: Historical Development of Antibody Drug Conjugates

Figure 1-2: Approval History of Commercially Available Antibody Drug Conjugates

Figure 1-3: Classification of Antibody Drug Conjugates

Figure 2-1: Therapeutic Index – Antibody Drug Conjugate vs. Cytotoxic Drug

Figure 3-1: Global – Antibody Drug Conjugate Market (US$ Billion), 2019-2023*

Figure 3-2: Global – Sales of ADCs for Breast Cancer v/s other indications (%), 2022

Figure 3-3: Global – Antibody Drug Conjugate Market Forecast (US$ Billion), 2023 –

2029

Figure 4-1: Tubulis - P5 Conjugation Platform Antibody

Figure 4-2: US – Sales of Cancer Antibody Drug Conjugates (US$ Million), 2023

Figure 4-3: US – Sales of Cancer Antibody Drug Conjugates (%), 2023

Figure 4-4: US – Sales of Cancer Antibody Drug Conjugates (US$ Million), 2022

Figure 4-5: US – Sales of Cancer Antibody Drug Conjugates (%), 2022

Figure 4-6: Pinot Bio - PINOT-ADCTM Platform Working Mechanism

Figure 4-7: Alteogen - NexMabandtrade; ADC technology

Figure 4-8: Canada – Cancer Incidence and Death, 2021

Figure 4-9: Adcetris - Canada Patents Numbers Approval and Expiration Dates

Figure 4-10: Padcev - Canada Patents Approval and Expiration Dates

Figure 4-11: Polivy - Canada Patents Numbers Approval and Expiration Dates

Figure 4-12: Enhertu - Canada Patents Numbers Approval and Expiration Dates

Figure 4-13: Trodelvy - Canada Patents Numbers Approval and Expiration Dates

Figure 4-14: Japan – Cancer Incidence and Death, 2022

Figure 6-1: Mylotarg – FDA Approval, Withdrawal and Re-Approval Year

Figure 6-2: Mylotarg – Approval Year by Region

Figure 6-3: UK - Cost of Supply of Mylotarg 5 mg Intravenous Powder (GBP/US$),

May’2023

Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May’2023

Figure 6-5: Mylotarg – Number of Induction Cycle and Consolidation Cycle Required

for Treatment of Newly Diagnosed De Novo CD33-positive AML

Figure 6-6: Mylotarg – Cost of Induction Cycle, Consolidation Cycles and Full

Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May’2023

Figure 6-7: Mylotarg – Recommended Number of Induction and Continuation Cycle for

Treatment of Newly Diagnosed CD-33 Positive AML

Figure 6-8: Mylotarg – Length of Induction and Continuation Cycle for Treatment of

Newly Diagnosed CD-33 positive AML (Days)

Figure 6-9: Mylotarg – Recommended Dose of Initial Dose and Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)

Figure 6-10: Mylotarg – Cost of Induction Phase and Continuation Phase and Full

Treatment Cost of CD-33 positive AML (US$), May’2023

Figure 6-11: Mylotarg – Cost of Single Dose and Full Treatment Cost of Relapsed and

Refractory CD33 Positive AML, May’2023

Figure 6-12: US - Adcetris Orphan Drug Designation Approval Year by Indication

Figure 6-13: US - Adcetris FDA Approval Year by Indication

Figure 6-14: Adcetris - Approval Year by Region

Figure 6-15: Japan - Adcetris PMDA Approval Year by Indication

Figure 6-16: Adcetris - Patent Expiration by Region

Figure 6-17: Adcetris - Cost of Supply of Vial for Injection by Region (US$),

May’2023

Figure 6-18: Adcetris – Duration of Single Treatment Cycle and Full Treatment of

Stage III and IV Classical Hodgkin Lymphoma (Weeks)

Figure 6-19: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment

of Stage III and IV Classical Hodgkin Lymphoma (US$), May’2023

Figure 6-20: Adcetris – Duration of Single Treatment Cycle and Full Treatment of

Classical Hodgkin Lymphoma (Weeks)

Figure 6-21: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment

of Classical Hodgkin Lymphoma (US$), May’2023

Figure 6-22: Adcetris – Cost of Single Treatment Cycle and Full Treatment of

Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$),

May’2023

Figure 6-23: Adcetris – Duration of Single Treatment Cycle and Full Treatment of

Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)

Figure 6-24: Adcetris – Maximum Cost of Single Treatment Cycle and Full Treatment

of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), May’2023

Figure 6-25: US - Kadcyla FDA Approval Year by Indication

Figure 6-26: Kadcyla - Approval Years by Region

Figure 6-27: US - Kadcyla FDA Approval and Patent Expiration Year

Figure 6-28: US - Price for Single Unit of Kadcyla 100 mg and 160 mg Intravenous

Powder for Injection (US$), May’2023

Figure 6-29: UK - Price for Single Unit of Kadcyla 100 mg and 160 mg Intravenous

Powder for Injection (GBP/US$), May’2023

Figure 6-30: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early

Stage HER2+ Breast Cancer (Weeks)

Figure 6-31: Kadcyla – Average Cost of Single Treatment Cycle for Early Stage HER2

Breast Cancer in Human with Average Weight (US$), May’2023

Figure 6-32: Kadcyla – Recommended Dose after 1st and 2nd Dose Reduction (mg/kg)

Figure 6-33: Besponsa - Approval Year by Region

Figure 6-34: UK - Cost of Supply of Besponsa 0.9 mg Intravenous Powder (GBP/US$),

May’2023

Figure 6-35: Besponsa - Cost of Supply of Vial for Injection by Region (US$),

May’2023

Figure 6-36: Besponsa – Duration of Initial Treatment Cycle and Subsequent Cycles

(Days)

Figure 6-37: Besponsa – Recommended Dose for 1st, 8th and 15th Day of Initial

Treatment Cycle (mg/m2)

Figure 6-38: Besponsa – Cost of Single Unit and Full Cost of Initial Treatment Cycle

(US$), May’2023

Figure 6-39: Besponsa – Cost of Single Unit and Full Cost of Subsequent Treatment

(US$), May’2023

Figure 6-40: Besponsa – Duration of Treatment of ALL – After and Without HSCT

(Weeks)

Figure 6-41: Lumoxiti – Orphan Designation Years

Figure 6-42: Lumoxiti – Patent Expiry Years

Figure 6-43: Lumoxiti – Duration of Single Treatment Cycle and Full Treatment

(Weeks)

Figure 6-44: Lumoxiti – Cost of Single Dose, Single Treatment Cycle and Full

Treatment of Hairy Cell Leukemia (US$), May’2023

Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region

Figure 6-46: US - Polivy Orphan Drug Designation Approval and Exclusivity Year

Figure 6-47: Polivy - Approval Year by Region

Figure 6-48: US - Price for Single Unit of Polivy 30 mg and 140 mg Intravenous Powder

for Injection (US$), May’2023

Figure 6-49: UK - Price for Single Unit of Polivy 30 mg and 140 mg Intravenous Powder

for Injection (GBP/US$), May’2023

Figure 6-50: Polivy - Duration of Single Treatment Cycle and Full Treatment (Weeks)

Figure 6-51: Polivy – Cost of Single Dose, Single Treatment Cycle and Full Treatment

of Hairy Cell Leukemia with 30 mg Powder (US$), May’2023

Figure 6-52: Polivy – Cost of Single Dose, Single Treatment Cycle and Full Treatment

of Hairy Cell Leukemia with 140 mg Powder (US$), May’2023

Figure 6-53: Padcev - Approval Year by Region

Figure 6-54: US - Padcev FDA Approval and Patent Expiration Year

Figure 6-55: US - Price for Padcev 20 mg and 30 mg Intravenous Powder for Injection

(US$), May’2023

Figure 6-56: UK - Price for Padcev 20 mg and 30 mg Intravenous Powder for Injection

(GBP/US$), May’2023

Figure 6-57: Padcev – Average Cost of Single Dose and Single Treatment Cycle with 20

mg Powder (US$), May’2023

Figure 6-58: Padcev – Average Cost of Single Dose and Single Treatment Cycle with 30

mg Powder (US$), May’2023

Figure 6-59: Padcev – Recommended Minimum Dose and Dose after Reduction for

Urothelial Cancer (mg/Kg)

Figure 6-60: Padcev – Recommended Maximum Dose and Dose after Reduction for

Urothelial Cancer (mg)

Figure 6-61: Enhertu – FDA Orphan Drug Designation and Exclusivity Expiration Year

Figure 6-62: Enhertu - Approval Year by Region

Figure 6-63: US - Polivy FDA Approval Year by Indication

Figure 6-64: UK - Cost of Supply of Enhertu 100 mg Intravenous Powder (GBP/US$),

May’2023

Figure 6-65: Besponsa - Cost of Supply of Vial for Injection by Region (US$),

May’2023

Figure 6-66: Enhertu – Recommended Dose by Cancer Type (mg/Kg)

Figure 6-67: Enhertu – Average Cost of Single Treatment Cycle and Annual Treatment

Cost (US$), May’2023

Figure 6-68: Enhertu – Recommended Dose and Dose after Reduction for Breast

Cancer (mg/Kg)

Figure 6-69: Enhertu – Recommended Dose and Dose after Reduction for Gastric

Cancer (mg/Kg)

Figure 6-70: US - Trodelvy FDA Approval by Indication

Figure 6-71: Trodelvy - Approval Year by Region

Figure 6-72: Trodelvy - Patent Expiration by Region

Figure 6-73: Trodelvy – Average Cost of Single Dose, Single Treatment Cycle and

Annual Treatment Cost (US$), May’2023

Figure 6-74: Trodelvy – Recommended Dose and Dose after Reduction (mg/Kg)

Figure 6-75: Blenrep – FDA and EMA Orphan Drug Designations

Figure 6-76: Blenrep – FDA and EMA Approval

Figure 6-77: Blenrep - Cost of Supply of 100 mg Intravenous Powder in US, EU and UK

(US$), May’2023

Figure 6-78: Blenrep – Average Cost of Single Treatment Cycle and Annual Treatment

Cost (US$), May’2023

Figure 6-79: Blenrep – Recommended Dose and Dose after Reduction (mg/Kg)

Figure 6-80: Zynlonta - FDA and EMA Orphan Drug Designation Years

Figure 6-81: Zynlonta - FDA and EMA Approval Years

Figure 6-82: Zynlonta – Recommended Dose for Initial and Subsequent Cycles (mg/kg)

Figure 6-83: Zynlonta – Average Cost of Single Treatment Cycle and Annual Treatment

Cost (US$), May’2023

Figure 6-84: Tivdak – Average Cost of Single Treatment Cycle and Annual Treatment

Cost (US$), May’2023

Figure 6-85: Tivdak – Recommended Dose and Dose after Reduction (mg/Kg)

Figure 6-86: US - Price per Unit and Single Supply of Elahere 100 mg/20 mL

Intravenous Solution (US$), May’2023

Figure 6-87: UK - Price for Single Unit of Elahere 100 mg/20 mL Intravenous

Solution (GBP/US$), May’2023

Figure 6-88: Aidixi - China Approval Year and FDA Breakthrough Therapy Designation

Year

Figure 6-89: India - Price for Single Unit of Ujvira 100 mg and 160 mg Intravenous

Powder for Injection (INR/US$), May’2023

Figure 6-90: India - Price for Single Unit of Branded and Biosimilar Trastuzumab

Emtansine 100 mg Powder for Injection (INR/US$), May’2023

Figure 6-91: Ujvira - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)

Figure 6-92: Ujvira – Cost of Single Treatment Cycle with 100 mg and 160 mg Powder

for Early Stage HER2+ Breast Cancer (INR/US$), May’2023

Figure 6-93: Ujvira – Recommended Dose After 1st and 2nd Dose Reduction (mg/m2)

Figure 6-94: Akalux - Sakigake Designation and PMDA Approval Year

Figure 7-1: Global - Adcetris Annual Sales (US$ Million), 2019-2023

Figure 7-2: Global - Adcetris Quarterly Sales (US$ Million), 2022

Figure 7-3: Global - Padcev Annual Sales (US$ Million), 2019-2023

Figure 7-4: Global - Padcev Quarterly Sales (US$ Million), 2022

Figure 7-5: Global - Tivdak Annual Sales (US$ Million), 2021-2023

Figure 7-6: Global - Tivdak Quarterly Sales (US$ Million), 2022

Figure 7-7: Global - Polivy Sales Values (US$ Million), 2019-2023

Figure 7-8: Regional - Polivy Sales (US$ Million), Q1’2023

Figure 7-9: Regional - Polivy Annual Sales (%), Q1’2023

Figure 7-10: Global - Polivy Quarterly Sales (US$ Million), 2022

Figure 7-11: Regional - Polivy Annual Sales (US$ Million), 2022

Figure 7-12: Regional - Polivy Annual Sales (%), 2022

Figure 7-13: US – Polivy Annual Sales (US$ Million), 2019-2023

Figure 7-14: EU – Polivy Annual Sales (US$ Million), 2020-2023

Figure 7-15: ROW - Polivy Annual Sales (US$ Million), 2020-2023

Figure 7-16: US - Polivy Quarterly Sales (US$ Million), 2022

Figure 7-17: Europe - Polivy Quarterly Sales (US$ Million), 2022

Figure 7-18: ROW - Polivy Quarterly Sales (US$ Million), 2022

Figure 7-19: Global - Kadcyla Annual Sales Value (US$ Million), 2019-2023

Figure 7-20: Regional - Kadcyla Sales (US$ Million), Q1’2023

Figure 7-21: Regional - Kadcyla Annual Sales (%), Q1’2023

Figure 7-22: Global - Kadcyla Quarterly Sales (US$ Million), 2022

Figure 7-23: Regional - Kadcyla Annual Sales (US$ Million), 2022

Figure 7-24: Regional - Kadcyla Annual Sales (%), 2022

Figure 7-25: US – Kadcyla Annual Sales (US$ Million), 2019-2023

Figure 7-26: Europe – Kadcyla Annual Sales (US$ Million), 2020-2023

Figure 7-27: ROW - Kadcyla Annual Sales (US$ Million), 2020-2023

Figure 7-28: US - Kadcyla Quarterly Sales (US$ Million), 2022

Figure 7-29: Europe - Kadcyla Quarterly Sales (US$ Million), 2022

Figure 7-30: ROW - Kadcyla Quarterly Sales (US$ Million), 2022

Figure 7-31: Global - Besponsa Annual Sales (US$ Million), 2020-2023

Figure 7-32: Besponsa - Annual Sales by Region (US$ Million), Q1’2023

Figure 7-33: Besponsa - Quarterly Sales by Region (%), Q1’2023

Figure 7-34: Global - Besponsa Quarterly Sales (US$ Million), 2022

Figure 7-35: Regional - Besponsa Annual Sales (US$ Million), 2022

Figure 7-36: Regional - Besponsa Annual Sales (%), 2022

Figure 7-37: US - Besponsa Quarterly Sales (US$ Million), 2022

Figure 7-38: US - Besponsa Annual Sales (US$ Million), 2020-2023

Figure 7-39: Europe - Besponsa Quarterly Sales (US$ Million), 2022

Figure 7-40: Europe - Besponsa Annual Sales (US$ Million), 2020-2023

Figure 7-41: ROW - Besponsa Quarterly Sales (US$ Million), 2022

Figure 7-42: ROW - Besponsa Annual Sales (US$ Million), 2020-2023

Figure 7-43: Global - Enhertu Annual Sales (US$ Million), 2020-2023

Figure 7-44: Global - Enhertu Quarterly Sales (US$ Million), 2022

Figure 7-45: US - Enhertu Annual Sales (US$ Million), 2020-2023

Figure 7-46: US - Enhertu Quarterly Sales (US$ Million), 2022

Figure 7-47: Europe - Enhertu Annual Sales (US$ Million), 2020-2023

Figure 7-48: Europe - Enhertu Quarterly Sales (US$ Million), 2022

Figure 7-49: Japan - Enhertu Annual Sales (US$ Million), 2020-2023

Figure 7-50: Japan - Enhertu Quarterly Sales (US$ Million), 2022

Figure 7-51: Global - Trodelvy Annual Sales (US$ Million), 2020-2023

Figure 7-52: Global - Trodelvy Quarterly Sales (US$ Million), 2022

Figure 7-53: Regional - Trodelvy Annual Sales (%), 2022

Figure 7-54: Regional - Trodelvy Annual Sales (%), 2022

Figure 7-55: US - Trodelvy Annual Sales (US$ Million), 2020-2023

Figure 7-56: US - Trodelvy Quarterly Sales (US$ Million), 2022

Figure 7-57: Europe - Trodelvy Annual Sales (US$ Million), 2021-2023

Figure 7-58: Europe - Trodelvy Quarterly Sales (US$ Million), 2022

Figure 7-59: ROW - Trodelvy Annual Sales (US$ Million), 2022-2023

Figure 7-60: ROW - Trodelvy Quarterly Sales (US$ Million), 2022

Figure 7-61: Global - Zynlonta Annual Sales (US$ Million), 2021-2023

Figure 7-62: Global - Zynlonta Quarterly Sales (US$ Million), 2022

Figure 7-63: Global - Elahere Annual Sales (US$ Million), 2022-2023

Figure 7-64: Global - Blenrep Annual Sales (Euro/US$ Million), 2020-2023

Figure 7-65: Regional - Blenrep Sales (Euro/US$ Million), Q1’2023

Figure 7-66: Regional – Blenrep Annual Sales (Euro/US$ Million), 2022

Figure 7-67: Regional – Blenrep Annual Sales (%), 2022

Figure 7-68: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2022

Figure 7-69: US - Blenrep Annual Sales (Euro/US$ Million), 2020-2023

Figure 7-70: US - Blenrep Quarterly Sales (Euro/US$ Million), 2022

Figure 7-71: Europe - Blenrep Annual Sales (Euro/US$ Million), 2020-2023

Figure 7-72: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2022

Figure 8-1: Global – Antibody Drug Conjugate In Clinical Trials By Phase, 2023

Figure 8-2: Global– Antibody Drug Conjugate In Clinical Trials By Indication, 2023

Figure 8-3: Global – Antibody Drug Conjugate In Clinical Trials By Company, 2023

Figure 8-4: Global – Antibody Drug Conjugate In Clinical Trials By Patient Segment,

2023

Figure 8-5: Global Antibody Drug Conjugate In Clinical Pipeline By Country, 2023

Figure 11-1: Antibody Drug conjugates Market Drivers

Figure 11-2: Challenges for Antibody Drug conjugates Market

Table 3-1: Approved Cancer Antibody Drug Conjugates

Table 5-1: Breast Cancer – Candidates Under Clinical Development

Table 5-2: Lung Cancer – Some Candidates under Clinical development

Table 5-3: Lymphoma – Some Candidates under Clinical development

Table 5-4: Leukemia – Some Candidates under Clinical development

Table 5-5: Urothelial Cancer – Some Candidates under Clinical development

Table 5-6: Gastric Cancer – Some Candidates under Clinical development

Table 5-7: Recent FDA/EMA Designations to Investigational ADCs

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected